Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Recruiting

• Conditions: Gene Abnormality; Lymphoma

• Registration Number: NCT04263935
• Lead Sponsor: Henan Cancer Hospital

Brief Summary

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Detailed Description

This trial is a prospective non-interventional observational study. The Chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.

Study Timeline

• Study Start: 2019-01-03
• Study First Submitted: 2020-02-03
• Study First Submitted QC: 2020-02-08
• Study First Posted: 2020-02-11
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-18
• Last Update Posted: 2025-04-23
• Primary Completion: 2025-06-30
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Diagnosed as lymphoma (according to WHO 2017 classification criteria)
2. Life expectancy no less than 3 months
3. Agreeing to sign the written informed consents

Exclusion Criteria

1. Other malignant tumor history or active malignant tumor need be treated
2. Researchers determine unsuited to participate in this trial

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of driver gene abnormalities	from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months	the incidence of driver gene abnormalities by fixed gene testing technology

Secondary Outcome Measures

Name	Time	Method
objective response rate	from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months	the total proportion of patients with complete response (CR) and partial response (PR)
5-year overall survival	from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years	from the date of first patient was included to the date of death by any cause
Clinicopathological Characteristics	from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months	study data on clinicopathological characteristics related to incidence of driver gene abnormalities

Trial Locations

Locations (1)

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university; 🇨🇳 Zhengzhou, Henan, China